GUTS logo

FRACTYL HEALTH INC

GUTSNASDAQ
🏆 #4251 by market capUS Equity
$752.40▼ $29.80 (−3.96%)
Simulated price
🔔
Track GUTS
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 4.0%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$75M
Small Cap
📈Revenue Growth (YoY)
-100.0%
Declining
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
68
Fair
No chart data available for GUTS.

Trading Snapshot

Day Range
$749.35 – $757.53
52-Week Range
$0.38 – $2.45
Volume
$2.15B
Avg Volume
$1.61B
Shares Outstanding
158.6M
Next Earnings
Oct 23, 2026

Fundamentals Snapshot

Annual Revenue
$6M
Last Q Revenue
$2M
P/E Ratio
-0.4
P/S Ratio
0.0x
EPS (TTM)
$-0.67
Dividend Yield
0.00%
Dilution (1yr)
+214.6%

Why Investors Own GUTS

  • ✓High-growth profile — revenue up +54.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 65% gross margin and 25% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

GUTS logo

FRACTYL HEALTH INC

GUTS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▼ −100.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
46.2%▲ +29.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$97M▲ +3.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$91M▲ +35.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
153.4M▲ +214.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$20M▲ +$15M YoY
StockOtter · stockotter.space

About FRACTYL HEALTH INC

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100

Analyst Price Target

ⓘ
Average Target
$937.66
▲ +24.6% Upside
High Target$1,039.00
Low Target$756.29
Based on 38 analysts

Latest News & Updates

🚀
CNBC·2h ago

FRACTYL HEALTH INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift GUTS price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

FRACTYL HEALTH INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.